Ghost cell glaucoma after intravitreal bevacizumab for postoperative vitreous hemorrhage following vitrectomy for proliferative diabetic retinopathy

Ophthalmic Surgery Lasers and Imaging

Volumn 41, Issue 1, 2010, Pages 72-77

  Liu, Laura ^a,b   Wu, Wei Chi ^a,b   Yeung, Ling ^a,b   Wang, Nan Kai ^a,b   Kuo, Ya Hui ^a,b   Chao, An Ning ^a,b   Chen, Kuan Jen ^a,b   Chen, Tun Lu ^a,b   Lai, Chi Chun ^a,b   Hwang, Yih Shiou ^c   Chen, Yen Po ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; BEVACIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIABETIC RETINOPATHY; FEMALE; GHOST CELL GLAUCOMA; GLAUCOMA; GLAUCOMA SURGERY; HUMAN; INTRAOCULAR PRESSURE; MALE; MEDICAL RECORD REVIEW; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; VISUAL ACUITY; VITRECTOMY; VITREOUS HEMORRHAGE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DIABETIC RETINOPATHY; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA; HUMANS; INJECTIONS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; POSTOPERATIVE HEMORRHAGE; PROGNOSIS; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITRECTOMY; VITREOUS BODY; VITREOUS HEMORRHAGE;

EID: 76149106488     PISSN: 15428877     EISSN: None     Source Type: Journal    
DOI: 10.3928/15428877-20091230-13     Document Type: Article

References (28)

1. Novak MA, Rice TA, Michels RG, Auer C. Vitreous hemorrhage after vitrectomy for diabetic retinopathy. Ophthalmology. 1984;91:1485-1489.
2. Schachat AP, Oyakawa RT, Michels RG, Rice TA. Complications of vitreous surgery for diabetic retinopathy: II. Postoperative complications. Ophthalmology. 1983;90:522-530.
3. Ramezani AR, Ahmadieh H, Ghaseminejad AK, Yazdani S, Golestan B. Effect of tranexamic acid on early postvitrectomy diabetic haemorrhage; a randomised clinical trial. Br J Ophthalmol. 2005;89:1041-1044.
4. de Bustros S, Glaser BM, Michels RG, Auer C. Effect of epsilon-aminocaproic acid on postvitrectomy hemorrhage. Arch Ophthalmol. 1985;103:219-221.
5. Koutsandrea CN, Apostolopoulos MN, Chatzoulis DZ, Parikakis EA, Theodossiadis GP. Hemostatic effects of SF6 after diabetic vitrectomy for vitreous hemorrhage. Acta Ophthalmol Scand. 2001;79:34-38.
6. Joondeph BC, Blankenship GW. Hemostatic effects of air versus fluid in diabetic vitrectomy. Ophthalmology. 1989;96:1701-1706.
7. Yang CM, Yeh PT, Yang CH. Intravitreal long-acting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy. Ophthalmology. 2007;114:710-715.
8. Martin DF, McCuen BW 2nd. Efficacy of fluid-air exchange for postvitrectomy diabetic vitreous hemorrhage. Am J Ophthalmol. 1992;114:457-463.
9. Lee SY, Yoon YH, Lee HG, Chung H, Kim JG. Intravitreal triamcinolone acetonide in eyes with recurrent postvitrectomy diabetic vitreous hemorrhage. Am J Ophthalmol. 2006;142:501-503.
10. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113:1695.e1-15. 11. Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol. 2006;90:1542-1547.
11. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology. 2007;114:743-750.
12. Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2006;142:155-158.
13. Ishikawa K, Honda S, Tsukahara Y, Negi A. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye. 2009;23:108-111.
14. Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina. 2006;26:699-700.
15. Ruiz-Moreno JM, Montero JA, Lugo F, et al. Intravitreal bevacizumab in recurrent diabetic vitreous haemorrhage after vitrectomy. Acta Ophthalmol. 2008;86:231-232.
16. Yanyali A, Aytug B, Horozoglu F, Nohutcu AF. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol. 2007;144:124-126.
17. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90:1344-1349.
18. Quiroz-Mercado H, Ustariz-Gonzalez O, Martinez-Castellanos MA, et al. Our experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story. Semin Ophthalmol. 2007;22:109-125.
19. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group(PACORES). Graefes Arch Clin Exp Ophthalmol. 2008;246:81-87.
20. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina. 2004;24(suppl):S3-S19.
21. Shima C, Sakaguchi H, Gomi F, et al. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol Scand. 2008;86:372-376.
22. Jorge R, Costa RA, Calucci D, Cintra LP, Scott IU. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina. 2006;26:1006-1013.
23. Minnella AM, Savastano CM, Ziccardi L, et al. Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy. Acta Ophthalmol. 2008;86:683-687.
24. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006;26:275-278.
25. Arevalo JF, Maia M, Flynn H Jr, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008;92:213-216.
26. Arevalo JF, Wu L, Sanchez JG, et al. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye. 2009;23:117-123.
27. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer. 2007;7:475-485.
28. Verheul HM, Lolkema MP, Qian DZ, et al. Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res. 2007;13:5341-5347.